31 results about "Halcinonide" patented technology

The invention discloses an ointment for treating gynaopathy and dermatoses and a preparation method thereof. The externally-applied ointment is prepared from halcinonide preparation, menthol crystal and camphor which are utilized as raw materials according to a certain preparation technology, and is prepared from the following raw materials in parts by weight: 6 to 6.5 parts of halcinonide preparation, 15 to 20 parts of menthol crystal, 15 to 20 parts of camphor, 3 to 3.5 parts of edetate disodium, 20 to 40 parts of polyethylene glycol mono stearate, 0 to 3 parts of essence, 0 to 2 parts of carbomer, 0 to 2 parts of sodium bicarbonate and 15 to 25 parts of pure water. The externally-applied ointment is low in cost, has the effects of clearing away heat, eliminating dampness, dispelling the wind, killing worms, diminishing inflammation and relieving itching, has better treatment effects, has the characteristics of being easy to prepare, lower in cost and obvious in treatment effect, and can be used for treating the gynaopathy, such as vaginitis, cervicitis and cervical erosion, caused by various germs, and treating the dermatoses, such as tinea corporis, tinea cruris, tinea of feetand hands and various dermatitis, caused by various fungus infection. The externally-applied ointment has exact treatment effects, takes effect rapidly, is low in cost and convenient to use, and has no toxic and side effects, thus being worthy of popularization and application.

The invention belongs to the technical field of medicine and discloses a liquid medicine for relieving itching of various skin diseases, and a preparation method thereof in particular. The liquid medicine for relieving itching of various skin diseases is prepared by the following materials: sulfur, borneol, camphor, pricklyash peel, sessile stemona root, belvedere fruit, halcinonide solution, and medicinal alcohol B. The preparation method comprises the following steps: after the six medicines of sulfur, borneol, camphor, pricklyash peel, sessile stemona root and Belvedere fruit are ground into powder, halcinonide liquid is added then, and finally the obtained mixture is added into the medical alcohol B together for dipping for 24 to 48 hours. The materials of the invention are easily obtained and the preparation method is simple. The liquid medicine is preferentially prepared into a lotion and arrives the affected part directly to exert the effects of disinsection, rheumatism and itching relief, and sterilization; simultaneously the liquid medicine can stimulate the skin and improve the microcirculation and the regulation functions of human bodies, thereby removing pathological changes. A plurality of clinic treatment effects prove that the liquid medicine has wide application range, the cure rate of more than 95 percent, and extremely good effects.

The invention provides a prepration process of a halcinonide intermediate. The preparation process comprises the steps: taking a hydrofluoric acid-acetone mixed solvent as a solvent, slowly adding an intermediate N-3 at subzero 40 DEG C to subzero 30 DEG C, carrying out reaction for 4 to 8 hours after material feeding is completed, enabling the temperature to return to subzero 5 DEG C to 0 DEG C, continuously carrying out reaction for 10 to 30 min, slowly adding reaction fluid into a potassium carbonate solution after the reaction is completed, adjusting the PH value to 7.0 to 7.5, filtering and discharging a product, and drying the product to obtain the halcinonide intermediate with the structure as shown in formula N-5. According to the preparation process, a one-pot method is adopted for production, so that the production steps are effectively simplified, and the production period is shortened; the preparation process is more environment-friendly.

[A pharmaceutical composition comprises a synergistic combination of about 0.01-0.15% by wt. triamcinolone acetonide and about 0.04-0.3% by wt. halcinonide as active ingredients, in combination with a pharmaceutically acceptable carrier.]A pharmaceutical composition comprises a synergistic combination of at least about 0.01% by wt. triamcinolone acetonide and at least about 0.01% by wt. halcinonide as active ingredients therein, in combination with a pharmaceutically acceptable carrier.

The invention discloses a medicine composition for treating gastric ulcer. The medicine composition for treating gastric ulcer comprises the following main raw materials in parts by weight: 20-30 parts of astragalus extract, 5-15 parts of radix paeoniae alba extract, 8-12 parts of halcinonide, 8-14 parts of tea polyphenol, 4-6 parts of calcium gluconate, 17-23 parts of formononetin, 8-15 parts of ginkgolides, 2-7 parts of Schisantherin and 3-9 parts of rutin. The medicine has anti-inflammation and stomach restoration capability so as to achieve the complete recovery purpose, can treat both symptoms and roots causes, and is fast in effect, low in toxic and side effects and low in cost.

The invention discloses a method for the quantitative detection of halcinonide in cosmetics, which comprises the steps that: 1) halcinonide and butenolide II are added into chromatographic methanol to obtain a reference substance; 2) a butenolide II methanol solution is added into a centrifuge tube and then cosmetics to be detected are added into the centrifuge tube which is dried in a manner of blow; 3) an extraction reagent is added; 4) centrifugation is carried out to obtain all organic phase solutes; 5) the organic phase solutes are dissolved in a mobile phase and a liquid layer is obtained after centrifugation; 6) the reference substance obtained by the step 1) and the liquid layer by the step 5) are carried out high efficiency liquid chromatographic analysis respectively; 7) the content of halcinonide in cosmetics to be detected is equal to the absorption peak area ratio of the halcinonide and the butenolide II in the liquid layer which is multiplied by the concentration of the halcinonide in the reference substance and divided by the absorption peak area ratio of the halcinonide and the butenolide II in the reference substance. The method for halcinonide detection provided by the invention has the advantage of high accuracy.

The present invention is the production process of fluorizing Halcinonide with intermediate condensating and reducing as material. The technological process incldues fluorizing reaction with hydrogen fluoride and dimethyl methane amide solution, dilution with great amount of water, neutralization with ammonia water, filtering, and drying; recrystallization to refine through dissolution with mixed solvent of chloroform and methanol, concentration, addition of methanol for recrystallization; and filtering and drying to obtain the fluorized Halcinonide product. The said technological process has high yield and quality of the fluorized product.

Halcinonide cream is provided. The halcinonide cream comprises halcinonide adopted as the active component, solid in oil-phase components, a consistency modifier, a humectant, an emulsifier, an aseptic and water, and is characterized by also comprising edetate calcium disodium.

The invention provides a medicinal frost formulation for treating psoriasis and its preparing process, wherein the formulation is prepared from the following constituents (by weight proportions), aitan part, erythromycin ointment 33 parts, Triamcinolone ointment 33 parts, Halcinonide emulsifiable paste 33 parts, and is prepared through mixing and modulation.

The invention relates to the technical field of medicines, in particular to application of halcinonide and a derivative thereof in preparation of a medicine for treating and/or preventing cerebrovascular diseases. The halcinonide and the derivative thereof have a structural general formula shown in formula (I), and the treatment effect of the halcinonide and the derivative thereof on ischemic cerebral stroke is evaluated through an MCAO cerebral ischemia-reperfusion injury animal model. Experimental results show that the halcinonide and the derivatives thereof prednisone and testosterone propionate can significantly improve the score of animal neurological impairment and reduce the area of infarct focus, can be used for treating ischemic stroke, and have good clinical application prospects.

The invention relates to medicines, in particular to a skin disease treating medicine. The skin disease treating medicine comprises raw medicinal materials in parts by weight as follows: 0.2-1.6 partsof halcinonide, 2-10 parts of prednisone acetate, 0.1-0.6 parts of diphenhydramine hydrochloride, 80-160 parts of chloramphenicol, 30-120 parts of griseofulvin, 100-260 parts of sulfur and 0.5-1.0 part of dexamethasone. The invention further provides a preparation method of the skin disease treating medicine. The medicine is applicable to skin diseases caused by various fungal infection and can promote cell protein synthesis and healing. Clinical application observation data shows that the medicine has the treatment rate of 95% and the effective rate of 100%.

The invention provides a preparation method of halcinonide and an intermediate thereof. The preparation method of the halcinonide intermediate (namely a compound of a formula N-7) comprises the following steps: carrying out a chlorination reaction on a compound of a formula N-3 and a chlorination reagent, and then carrying out a fluorination reaction with a fluorine-containing reagent, wherein the reaction formula is disclosed in the invention, the chlorination reagent is selected from sulfonyl chloride of aromatic hydrocarbon and is specifically selected from at least one of benzene sulfonyl chloride, p-toluenesulfonyl chloride and p-chlorobenzene sulfonyl chloride, and the fluorine-containing reagent is hydrofluoric acid. The preparation method is efficient, green and environmentally friendly, the production period is shortened, a large amount of wastewater is reduced, the yield is improved, the production cost is reduced, clean production is achieved, the HPLC content of the halcinonide product reaches 99.0% or above, the content of any impurity is smaller than 0.10%, and the yield reaches 100% or above.

The invention provides application of a biomarker in preparation of a product for screening and diagnosing sexual precocity of children. The biomarker is prepared from one or more of halcinonide, corticosterone, cortisone, 11-deoxycorticosterone, 11-deoxycortisol, 17 alpha-hydroxyprogesterone, betasone butyrate, fludrocortisone acetate, methylprednisolone acetate, prednisolone acetate, hydrocortisone valerate, methyltestosterone and androstenedione (steroid). According to the application, a plurality of child samples are measured, and the result shows that specific compounds have significant difference between healthy children and precocious children, and the T test P value is less than 0.1, which shows that the contents of the compounds have significant difference. Therefore, the compounds with significant difference can be used as diagnostic markers for screening and diagnosing early sexual precocity of children.